Related Experiment Video
Updated: May 13, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Molecular biomarkers for predicting chemotherapy response in lung cancer
Jia Wei1, Baorui Liu, Andres Felipe Cardona
1Medical School of Nanjing University, Affiliated Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Department of Oncology, Zhongshan Road 321, Nanjing 210008, China +86 25 83317016 ; +86 25 83317016 ; baoruiliu@nju.edu.cn.
Background:
Chemotherapy in non-small-cell lung cancer (NSCLC) has reached a plateau, with no evidence of substantial improvement in survival. However, recent advances in the management of lung cancer have paved the way for the optimization of treatment. Several lines of evidence indicate that multiple genetic disturbances found in human cancer cell lines and in the tumors of NSCLC patients have a role as predictive markers for response and survival with chemotherapy regimens now in use.
Objective:
This review highlights relevant translational research findings on potential predictive markers in lung cancer with therapeutic impact in both the near and distant future.
Conclusion:
The next step is to develop clinical trials that will prospectively validate the benefits of customizing chemotherapy, which should translate into an improvement in outcome in NSCLC patients.
Insights
Identifying genetic markers can personalize non-small cell lung cancer (NSCLC) chemotherapy, improving patient survival. Future clinical trials will validate these predictive markers for customized treatment strategies.
Area of Science:
- Oncology
- Translational Research
Background:
- Chemotherapy for non-small cell lung cancer (NSCLC) has shown limited survival benefits.
- Advances in lung cancer management offer opportunities for treatment optimization.
- Genetic disturbances in NSCLC are emerging as potential predictive markers for chemotherapy response and survival.
Purpose of the Study:
- To review translational research on predictive markers in lung cancer.
- To highlight markers with current and future therapeutic impact.
Main Methods:
- Literature review of translational research findings.
- Analysis of genetic markers in NSCLC cell lines and patient tumors.
Main Results:
- Genetic markers show potential for predicting chemotherapy response and survival in NSCLC.
- Translational research is identifying key disturbances with therapeutic relevance.
Conclusions:
- Prospective clinical trials are needed to validate customized chemotherapy benefits.
- Personalized treatment strategies are expected to improve outcomes for NSCLC patients.
